<code id='474306544F'></code><style id='474306544F'></style>
    • <acronym id='474306544F'></acronym>
      <center id='474306544F'><center id='474306544F'><tfoot id='474306544F'></tfoot></center><abbr id='474306544F'><dir id='474306544F'><tfoot id='474306544F'></tfoot><noframes id='474306544F'>

    • <optgroup id='474306544F'><strike id='474306544F'><sup id='474306544F'></sup></strike><code id='474306544F'></code></optgroup>
        1. <b id='474306544F'><label id='474306544F'><select id='474306544F'><dt id='474306544F'><span id='474306544F'></span></dt></select></label></b><u id='474306544F'></u>
          <i id='474306544F'><strike id='474306544F'><tt id='474306544F'><pre id='474306544F'></pre></tt></strike></i>

          Home / comprehensive / fashion

          fashion


          fashion

          author:fashion    Page View:33
          Sammy Kimball for STAT

          Can biotech startups survive a downturn? Is Covid-19 a good business? And when did ophthalmology get so dramatic?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss what some recent layoffs and a reverse merger mean for biotech in 2023. We’ll also discuss the latest news in the life sciences, including a dramatic saga in ocular medicine, the volatile business of Covid-19, and some major milestones in gene therapy.

          advertisement

          For more on what we cover, here’s the news on Celsius Therapeutics; here’s more on EQRx; here’s the latest on Apellis Pharmaceuticals; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].